How many clinical trials are studying Interleukin-2?

12 recruiting trials in our tracked data involve Interleukin-2.

What conditions is Interleukin-2 being studied for?

In our tracked recruiting trials, Interleukin-2 is being studied in trials for Breast Cancer, Breast Neoplasms, Lung Cancer.

Interleukin-2: clinical trials recruiting now

Q: Is Interleukin-2 FDA-approved?

Yes. According to the FDA drug label available through openFDA, Interleukin-2 is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Interleukin-2 appears in the FDA drug-label database. Marketed as GUNA-IL 11.

FDA-approved use

Take 15 minutes before meals.

FDA label via openFDA

Phase breakdown

Phase 1 11 Phase 2 9

Conditions being studied

Condition	Trials
Breast Cancer · Interleukin-2 for Breast Cancer	5
Breast Neoplasms · Interleukin-2 for Breast Neoplasms	4
Lung Cancer · Interleukin-2 for Lung Cancer	3
Melanoma	2
Breast Cancer Metastatic	1
Breast Cancer Triple Negative	1
Breast Carcinoma	1
Colon Cancer	1
Colorectal Cancer	1
Esophageal Cancer	1
Esophageal Cancer Metastatic to Bone	1
Esophageal Cancer Metastatic to Liver	1
Esophageal Cancer Metastatic to Lung	1
Inoperable Disease	1
Lung Cancer Metastatic	1

Recruiting trials involving Interleukin-2

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
NCT07255664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
NCT06530303 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT06961357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
NCT07192900 · Phase: Phase 1 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 1 location
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT04562129 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT06121557 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

Is Interleukin-2 FDA-approved?

Yes, marketed as GUNA-IL 11.

How many recruiting trials involve Interleukin-2?

12 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.